Related Experiment Video
Updated: Jan 24, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy
Ronay Thomas1, Robin Dulman1,2, Angela Lewis1
1Department of Hematology-Oncology, Pediatric Specialists of Virginia, Falls Church, Virginia.
Insights
Hydroxyurea (HU) is safe and effective for infants with sickle cell disease (SCD). Early HU treatment in infancy significantly reduces SCD complications, making community practice implementation feasible.
Area of Science:
- Pediatric Hematology
- Sickle Cell Disease Management
- Pharmacological Interventions
Background:
- Hydroxyurea (HU) is known to increase fetal hemoglobin (HgbF) and alleviate symptoms in sickle cell disease (SCD).
- Existing studies confirm the safety and efficacy of HU in pediatric populations.
- There is a need to integrate HU initiation into routine community healthcare for infants with SCD.
Purpose of the Study:
- To evaluate the feasibility and effectiveness of initiating Hydroxyurea (HU) therapy in infants diagnosed with sickle cell disease (SCD).
- To assess the impact of early HU intervention on disease complications and clinical outcomes in young children with SCD.
Main Methods:
- A prospective longitudinal study was conducted, tracking 24 infants with HgbSS who began HU treatment before age one.
- Data on clinical course and outcomes were collected over 95 person-years of follow-up.
- Outcomes included hemoglobin levels, HgbF percentages, hospitalizations, emergency department visits, and specific SCD complications.
Main Results:
- Infants receiving HU by age one showed sustained increases in hemoglobin and HgbF levels.
- A significant reduction in hospitalizations and emergency department visits for SCD-related complications was observed after HU initiation.
- No cases of acute chest syndrome, abnormal transcranial Doppler findings, or strokes occurred; pain episodes requiring medical attention were eliminated.
Conclusions:
- Initiating Hydroxyurea (HU) therapy in infancy for children with sickle cell disease (SCD) is a feasible strategy for community practice.
- Early HU treatment is highly effective in preventing serious disease complications, improving the clinical course of SCD in early childhood.
Background:
Hydroxyurea (HU) increases fetal hemoglobin (HgbF) and ameliorates sickle cell disease (SCD) symptoms. Studies have demonstrated the safety and efficacy of HU in infants and children. Initiation of HU in infancy for children with SCD needs to be implemented in community practice.
Procedure:
Starting in 2011, the Pediatric Sickle Cell Program of Northern Virginia initiated HU in infants with SCD. A prospective longitudinal database tracked the clinical course and outcomes.
Results:
Twenty-four children with HgbSS who started HU by age 1 were continuously followed for a total of 95 person-years. Age at the time of analysis ranged from 2 to 7 years. Average hemoglobin at 6-month intervals ranged from 9.5 + 1.9 to 10.7 + 0.8 g/dL, and average HgbF ranged from 27.8 + 5.0% to 34.1 + 6.6%. Twenty-seven hospitalizations occurred (0.28/person-year), all before age 3, including 19 (70%) for fever or infection, five (19%) for splenic sequestration, and one (4%) for pain in an infant prior to starting HU. The treat-and-release emergency department visits totaled 68 (0.72/person-year), including 62 visits (91%) for fever, infection, or viral illness, and two visits (3%) for pain/dactylitis in infants before HU initiation. Splenic sequestration accounted for all five transfusions. No pain episodes requiring medical attention were documented after HU initiation. No complicated acute chest syndrome, no abnormal or conditional transcranial Doppler ultrasound, and no overt strokes occurred.
Conclusion:
Implementation of HU in infancy for patients with SCD in community practice is feasible and is highly effective in preventing disease complications.
Related Concept Videos
Socioemotional Development during Infancy
Primary Temperament Types
Longitudinal Research
Longitudinal Studies
Drug Dosing: Infants and Children
EPS and iPS Cells in Disease Research
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

